Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LiveSpo DIA30
- Development stage
- Unknown
- Lead developer
- Livespo Global
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
LiveSpo DIA30 is a multi-strain probiotic supplement developed by LiveSpo Global for the supportive treatment of acute diarrhea and digestive disorders. The formulation consists of three *Bacillus* spore-forming bacteria: *Bacillus subtilis*, *Bacillus clausii*, and *Bacillus coagulans*, delivered at a concentration of 5 billion CFU per 5 mL ampoule. The product utilizes proprietary Pre-activated Spore Probiotic Liquid (SPL) technology, which allows the spores to germinate rapidly upon reaching the gastrointestinal tract. Its mechanism of action involves restoring healthy gut microbiota balance and reducing the levels of pro-inflammatory cytokines, thereby shortening the duration of diarrhea and improving clinical outcomes, particularly in children with persistent symptoms.
- Brand names
- LiveSpo DIA30
- Other names
- LiveSpo Global-gut microbiota / intestinal flora-probiotic supplement (Bacillus spore-forming bacteria)-oral-acute diarrhea / diarrhea support
Beyond the preview
Go deeper on LiveSpo DIA30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LiveSpo DIA30.